Johnson & Johnson Unveils New Data Showing Nipocalimab is the First and Only Investigational FcRn Blocker With Potential to Reduce Systemic Lupus Erythematosus Activity in a Phase 2 Study
January 07, 2026
January 07, 2026
RARITAN, New Jersey, Jan. 7 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for ste . . .
* * *
Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for ste . . .